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represents a novel strategy to reduce gut GVHD by direct
protection of intestinal epitheliumwithout limiting immune
function post-transplant.Table 1
DBY UTY ZFY EIF1AY RPS4Y Any-HY
NMDP
(n[289)
63 (22%) 112 (39%) 22 (8%) 7 (2%) 42 (15%) 143 (49%)
Stanford
(n[90)
20 (22%) 32 (36%) 4 (4%) 1 (1%) 8 (9%) 46 (51%)
Table 2
(NMDP) cGVHD aGVHD Relapse TRM OS
HY-score HR P HR P HR P HR P HR P
0 (n[146) 1 - 1 - 1 　 1 - 1 -
1 (n[75) 1.34 0.15 1.17 0.46 1.22 0.54 0.85 0.44 0.98 0.89
2 (n[39) 1.12 0.65 1.25 0.39 0.63 0.31 0.62 0.078 0.81 0.39
3 to 4
(n[29)
1.32 0.37 1.64 0.064 1.85 0.19 1.3 0.34 1.48 0.09950
Targeting Sag in Donor T Cells As a Novel Strategy for
Reducing Gvhd
Nathan Mathewson 1,2, Tomomi Toubai 1, Yaping Sun 1,
Ying Wang 1, Katherine Oravecz-Wilson 1, Guoqing Hou 1,
Julia Wu 1,2, Pavan Reddy 1,3. 1Internal Medicine - Hematology
and Oncology, University of Michigan Comprehensive Cancer
Center, Ann Arbor, MI; 2Graduate Program in Immunology,
University of Michigan Medical School, Ann Arbor, MI; 3Adult
Blood and Marrow Transplant Program, University of Michigan,
Ann Arbor, MI
Neddylation is crucial for the degradation of certain proteins.
However its role in regulating T cells is unknown. Neddyla-
tion is mediated by cullin-RING ligase (CRL) protein complex,
an E3 ubiquitin ligase and its critical adapter element, SAG
protein (sensitive to apoptosis gene protein). We explored
the role of SAG and thus neddylation in T cells by utilizing
two different, but complementary approaches, namely,
genetic knock-out and chemical inhibition with small
molecule. The T cell speciﬁc SAG KO animals were generated
by crossing B6 SAGﬂ/ﬂ mice with B6 LCK-Cre mice. The KO
animals were viable. The splenic and thymic analyses
showed no signiﬁcant differences in the numbers of
conventional T cells (Tcons) and Tregs between the KO and
WT animals. In vitro functional analysis of Tcons, however,
revealed that stimulation with either allogeneic splenocytes
or by a-CD3 and a-CD28 antibody, SAG-/- T cells showed
signiﬁcantly decreased proliferation (P<0.002). Phenotypic
analysis following stimulation demonstrated that SAG-/- T
cells showed reduced expression of CD69, CD44 and greater
expression of CD62L when compared to WT-T cells (P<0.04).
The KO-T cells also demonstrated reduced expression of T
effector signature cytokines, IL-17, IFN-g and IL-4. Similar
reduction in proliferation, activation marker expression and
release of cytokines was observed when the WT-T cells were
treated with small molecule inhibitor of neddylation,
MLN4924.
We next determined the in vivo relevance of SAG and
neddylation in Tcons by utilizing the MHC disparate
(B6/BALB/c) model of allogeneic BMT. The BALB/c animals
were lethally irradiated and transplanted with TCD BM from
either syngeneic or allogeneic WT-B6 animals along with
5x105 splenic T cells from either the WT B6 or SAG-/- B6
animals. The allogeneic animals that received SAG-/- T cells
demonstrated markedly reduced clinical GVHD and signiﬁ-
cantly increased survival when compared to those that
received WT-B6 T cells (P<0.001). Similar results were
observed in B6/B6D2F1 model. To further conﬁrm our
results and to determine potential translational application,
we utilized the small molecule MLN4924, once again in the
B6/BALB/c system. The recipient mice were lethally irra-
diated and received 5 doses of MLN4924 (20mg/kg, day-1 to
day +3 of BMT) along with WT-B6 T cells. Mice receiving
MLN4924 demonstrated signiﬁcantly decreased clinical
GVHD and improved survival. Our studies thus demonstrate
that SAG is a novel molecular target for regulating T cell re-
sponses and mitigating GVHD. Furthermore, the clinical
availability of the small molecule, MLN4924, suggests that
this strategy could be tested in carefully designed human
clinical trial for attenuating GVHD.51
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Background: Transplant of male recipients from female
donors (F>M HCT) is well known as a risk factor for devel-
oping chronic graft-versus-host disease (cGVHD).We have so
far suggested that B cell response against minor histocom-
patibility antigens encoded on the Y chromosome, called H-Y
antigens, develops following F>M HCT and associates with
cGVHD. Here, we hypothesize that pre-sensitization to HY-
antigen in a female donor may affect the post-HCT HY-IgG
development and clinical outcomes following F>MHCT. This
study uses our novel HY microarray to determine the prev-
alence and impact of donor HY-IgG.
Methods: Wemeasured IgG against 5 HY antigens (DBY, UTY,
ZFY, EIF1AY, &RBS4Y) in289 femaledonors (age:18-60) of high
resolution 8/8 HLA-matched HCT facilitated by the NMDP be-
tween 1990-2002 and assessed the impact of HY seropositivity
on cumulative cGVHD incidence and other clinical outcomes.
In addition, we studied 90 Stanford adult female donors
and their corresponding male recipients between 2005 and
2012 who survived without relapse for at least 3m post-HCT
and assessed the association of HY-IgG development be-
tween pre- and post-HCT. The cut-off value for seropositivity
was deﬁned as Q3 + 2xIQR, determined from plasma of 60
maledonors. HY-score was deﬁned as the cumulative num-
ber of targeted HY antigens.
Results: Prevalence of HY-IgGs in female donors is shown
in Table1. Half of female donors had at least one of 5
HY-IgG(s). Univariate analyses of NMDP cohort showed that
individual HY-IgGs in female donors were not associated
with cGVHD. Focusing on increasing HY-score, we did not
detect association with cGVHD nor other clinical outcomes
(Table 2). This absence of association was also observed in
Stanford cohort. Further, we were unable to show the
